This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it Affected Product Product name Part number Lot numbers Breathing circuit set, coaxial 260128 199675 Breathing circuit set, coaxial 260128 199676 What to Do Do not use any breathing circuits from affected lots. Replace any affected breathing circuits in use with patients and discard the a

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract with data from the company's single-arm, Phase 1/2 trial of darovasertib in combination with crizotinib in first-line metastatic uveal melanoma (mUM) was accepted for an oral presentation at the 2025 Society for Melanoma Research Congress (SMR), taking place on October 25-28 in Amsterdam. The presentation will include

BEIJING and SHANGHAI and BOSTON, Aug. 29, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced its interim results for the six months ended June 30, 2025. During the reporting period, the Company achieved revenue of RMB45.7 million, representing a 100% increase compared with the same period in 2024. Research and development (R&D) expenses amounted to RMB93.2 million. The net loss for the first half of 2025 was RMB59.0 million, narrowing by 65.1% compared with the same period in 2024.

RYE, EAST SUSSEX, UNITED KINGDOM, August 29, 2025 / EINPresswire.com / -- BirchBioMed Inc., a leading biopharmaceutical company and expert in the development of products for scarring and other fibrosis-related disorders, is thrilled to announce Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario, Canada, as the first contracted clinical trial site for its Phase II/III randomized study of the naturally-based compound, FS2. The trial (ClinicalTrials.gov identifier: NCT06807021 ) wi

Pfizer plans to discontinue Vyndaqel, leaving the high-dose Vyndamax as the only tafamidis brand on the U.S. market. Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM).Pfizer will discontinue Vyndaqel in the U.S. by the end of 2025, multiple amyloidosis patient groups alerted their members on social media earlier this month.The move will leave the high-dose Vyn

Eli Lilly and JD Health said they plan to continue to grow their collaboration to offer treatments and care services to Chinese patients across more disease areas. Amid a growing push for more direct-to-consumer access to some of the world’s most popular drugs, Eli Lilly has inked a deal with China’s JD Health to sell its obesity, Type 2 diabetes and alopecia areata meds in the country through a digital health platform.The platform will aim to serve as a “one-stop” shop for chronic disea

AstraZeneca has purportedly declined to re-up its contract with the school and allegedly “absconded with the University’s property”—a pair of influenza master strains—which it continues to market via FluMist. As AstraZeneca charts a lucrative new path for FluMist with a self-administration nod and an at-home delivery service for the nasal spray-based influenza vaccine, the school that had a hand in the drug’s provenance is demanding its dues.The University of Michigan is suing AZ over cl

This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product What to Do Do not use Ambu SPUR II resuscitators from affected lots. Identify and discard resuscitators from affected lots. On July 8, 2025, Ambu sent all affected customers an Urgent Field Safety Notice recommending the following actions: Identify if any Ambu SPUR II

MINNEAPOLIS, Aug. 29, 2025 /PRNewswire/ -- Phraxis, Inc., a leader in vascular access innovation, today announced the successful completion of the first commercial case using the EndoForce™ Anastomotic Connector, marking a historic milestone in the treatment of dialysis patients worldwide. The procedure, performed by Dr. Ari Kramer, Vascular Access Surgeon and early clinical pioneer of EndoForce™, took place at Spartanburg Regional Medical Center in Spartanburg, South Carolina. Continue Reading

Chinese authorities are already reviewing filings for potential approval of BeOne Medicines’ sonrotoclax. \n A phase 1/2 trial of BeOne Medicines’ sonrotoclax has hit its primary endpoint, furthering the biotech’s plans to launch the first BCL2 inhibitor for use in mantle cell lymphoma (MCL).The single-arm study enrolled 125 adults with relapsed or refractory MCL. Participants had previously tried anti-CD20 therapy and a BTK inhibitor. The study met its overall response rate pri